Progressive multifocal leukoencephalopathy (JC virus)
PML · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
PML is a demyelinating CNS infection caused by JC polyomavirus reactivation in profound immunosuppression (advanced HIV, natalizumab, other biologics, haematological malignancy). There is no specific antiviral; restoring immune function is the only effective strategy.
Red flags
- Rapidly progressive hemiparesis, aphasia or visual field loss
- New seizures
- Deterioration after immune recovery (IRIS)
- Coma or brainstem involvement
- Recent natalizumab with rising JC antibody index
Assessment
Differential diagnosis
- HIV encephalopathy
- CNS lymphoma
- Cerebral toxoplasmosis
- CMV or HSV encephalitis
- Immune reconstitution inflammatory syndrome
- Demyelination/MS relapse
Investigations
- MRI brain (asymmetric subcortical white-matter lesions, no enhancement/mass effect typically)
- CSF JC virus PCR
- CD4 count and HIV viral load
- Review of immunosuppressive/biologic exposure (e.g. natalizumab, JC antibody index)
- Brain biopsy if PCR negative but high suspicion
- Baseline neurological function assessment
Management
- Suspect in immunosuppressed patient with progressive focal neurological deficit
- Obtain MRI brain and CSF JC virus PCR
- Review all immunosuppressant exposure, especially natalizumab/biologics
- Stop or reverse the causative immunosuppressant where possible (e.g. plasma exchange for natalizumab)
- In HIV, start or optimise ART urgently to achieve immune recovery
- Anticipate and manage immune reconstitution inflammatory syndrome (may use corticosteroids)
- Provide neurorehabilitation and supportive care
- Monitor clinically and with repeat imaging
- Consider experimental immune-based therapies in specialist centres
- Manage seizures and complications as they arise
- Counsel patient and family on guarded prognosis
- Multidisciplinary neurology/ID involvement
Drugs & doses
Optimised combination antiretroviral therapy (HIV-associated PML) - regimen as per resistance
Corticosteroids (e.g. methylprednisolone) for PML-IRIS inflammatory deterioration
Mirtazapine 15-30 mg PO at night (adjunct, 5-HT2A blockade - limited evidence)
No proven specific antiviral (cidofovir/cytarabine not recommended)
Disposition
Admit for workup; neurology and ID co-management; specialist centre referral.
Complications & pitfalls
- Severe permanent neurological disability
- PML immune reconstitution inflammatory syndrome
- Seizures
- Death
- Aspiration and immobility complications
Exam pearls
- Restoring immunity is the mainstay; there is no effective antiviral
- Natalizumab-associated PML warrants plasma exchange to remove drug
- IRIS may paradoxically worsen clinical state as the lesion becomes inflamed
- Enhancement on MRI is atypical and suggests IRIS or alternative diagnosis
- JC antibody index stratifies PML risk in patients on natalizumab
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.